GENERAL DISCUSSION 227 10 25. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and ondemand defense against excitotoxicity. Science. 2003;302(5642):84-88. 26. Rouzer CA, Ghebreselasie K, Marnett LJ. Chemical stability of 2-arachidonylglycerol under biological conditions. Chem Phys Lipids. 2002;119(1-2):69-82. 27. Willoughby KA, Moore SF, Martin BR, Ellis EF. The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther. 1997;282(1):243-247. 28. Rea K, Roche M, Finn DP. Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol. 2007;152(5):633-648. 29. Szabo B, Schlicker E. Effects of Cannabinoids on Neurotransmission. In: Pertwee RG, ed. Cannabinoids. Springer Berlin Heidelberg; 2005:327-365. 30. Engel MA, Izydorczyk I, Mueller-Tribbensee SM, et al. Inhibitory CB1 and activating/ desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin. Neuropeptides. 2011;45(3):229-237. 31. AkermanS,KaubeH,GoadsbyPJ.Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascularmediated nociception. J Pharmacol Exp Ther. 2004;309(1):56-63. 32. Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol. 2004;142(8):1354-1360. 33. Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3216-3228. 34. Starowicz K, Przewlocka B. Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3286-3299. 35. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol. 2001;41:661-690. 36. Moriyama T, Higashi T, Togashi K, et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain. 2005;1:3. 37. Ma W, St-Jacques B, Rudakou U, Kim YN. Stimulating TRPV1 externalization and synthesis in dorsal root ganglion neurons contributes to PGE2 potentiation of TRPV1 activity and nociceptor sensitization. Eur J Pain. 2017;21(4):575-593. 38. Jang Y, Kim M, Hwang SW. Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. J Neuroinflammation. 2020;17(1):30. 39. Jenkins DW, Feniuk W, Humphrey PP. Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol. 2001;134(6):12961302. 40. Neeb L, Hellen P, Boehnke C, et al. IL1beta stimulates COX-2 dependent PGE(2) synthesis and CGRP release in rat trigeminal ganglia cells. PLoS One. 2011;6(3):e17360. 41. Jenkins DW, Langmead CJ, Parsons AA, Strijbos PJ. Regulation of calcitonin generelated peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci Lett. 2004;366(3):241-244. 42. Woodward DF, Carling RW, Cornell CL, et al. The pharmacology and therapeutic relevance of endocannabinoid derived cyclooxygenase (COX)-2 products. Pharmacol Ther. 2008;120(1):71-80. 43. Del Fiacco M, Quartu M, Boi M, et al.TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. J Neurol Neurosurg Psychiatry. 2015;86(4):393-397. 44. Benemei S, Dussor G. TRP Channels and Migraine: Recent Developments and New Therapeutic Opportunities. Pharmaceuticals (Basel). 2019;12(2) 45. Tfelt-Hansen P, Messlinger K. Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect. Br J Clin Pharmacol. 2019;85(11):2487-2498.
RkJQdWJsaXNoZXIy MTk4NDMw